Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Latar Belakang: Pasien yang menjalani hemodialisis (HD) rutin berisiko terinfeksi virus hepatitis C (VHC). Infeksi VHC kronik meningkatkan mortalitas terkait penyakit hati kronik dan kardiovaskuler.Direct Acting Anti-viral(DAA) merupakan pilihan terapi infeksi VHC pada pasien Penyakit Ginjal Kronik, tetapi sebagian besar DAA mengandung metabolit yang diekskresi melalui ginjal. Grazoprevir-elbasvir (GZR-EBV) adalah pilihan utama DAA untuk terapi infeksi VHC pada pasien HD rutin dengan keberhasilanSustained Virological Response(SVR)>90% dan adverse eventyang minimal. Namun masih belum diketahui keberhasilan terapi GZR-EBV dan faktor-faktor yang mempengaruhinya pada pasien HD rutin di Indonesia yang memiliki perbedaan genotip VHC dan genotip pasien HD. Tujuan: Menilai keberhasilan terapi GZR-EBV dan faktor-faktor yang berhubungan dengan keberhasilan terapi pada pasien HD dengan Hepatitis C kronik dan mengetahui gambaran adverse event. Metode: Penelitian ini merupakan studi kohort prospektif observasional pada pasien HD dengan Hepatitis C kronik. Data klinis dan pemeriksaan penunjang dikumpulkan dan dianalisis untuk mengetahui respon terapi, dan untuk mengetahui asosisasi antara faktor muatan virus RNA VHC, derajat fibrosis dan lama HD dengan SVR12. Hasil: Didapatkan 75 subyek yang memenuhi kriteria inklusi. Rerata usia 50,2±13,2 tahun, jenis kelamin perempuan lebih banyak ditemukan. Lama HD 6,9±4,7tahun. Keberhasilan SVR12 mencapai 97,2%. Risiko relatif keberhasilan SVR12 berdasarkan muatan virus <800.000 IU/mL dibandingkan³800.000 IU/mL adalah 1,01 (IK 95% 0,93-1,10; p=1,00), derajat fibrosis hati skor Metavir F4 dibandingkan F0-F3 adalah 0,95 (IK 95% 0,81-1,10; p=0,35) dan lama HD <3 tahun dibandingkan ≥3 tahun adalah 1,04 (IK 95% 0,99-1,09; p=1,00). Adverse eventobat minimal. Simpulan: Terapi GZR-EBV pada pasien hepatitis C kronik yang menjalani HD rutin menunjukkan efektifitas yang baik, dengan adverse eventminimal. Keberhasilan terapi tidak dipengaruhi oleh jumlah muatan virus, derajat fibrosis dan lama HD. ......Background: Patients on hemodialysis are at risk of hepatitis C virus (HCV) infection. Chronic hepatitis C virus infection increases mortality related to chronic liver and cardiovascular disease. Direct Acting Anti-viral (DAA) is a therapeutic choice for HCV infection in patients with Chronic Kidney Disease, but most of the DAA metabolite eliminated by the kidney. Grazoprevir-elbasvir is the drug of choice for chronic HCV infection in hemodialysis patients, and have Sustained Virological Response (SVR) >90% and less adverse event. However, therapeutic response and the factors that influence this drug in routine HD patients in Indonesia is still unknown. Objective: Assessing therapeutic response and side effects of grazoprevir-elbasvir for Hepatitis C Virus in routine hemodialysis patient. Methods: Observational cohort prospective study on all patients with Chronic HCV infection with routine HD. Clinical and laboratory data were analyzed for therapeutic response and determined the factors that related to therapeutic response. Viral load, degree of liver fibrosis, and duration of HD treatment and relation with response SVR12 as analyzed using bivariate method of statistical analysis. Results: Seventy-five subjects met inclusion criteria. The average age is 50.2±13.2 years, subjects with female were more than male. The average duration of HD is 6.9±4.7 years. SVR12 achievement is 97.2%. Relative risk of SVR12 based on viral load <800,000 versus ³800,000 were 1.01 (95%CI 0.93-1.10 p=1.00), Score Metavir F4 versus to F0-F3 were 0.95 (95%CI 0.81-1.10 p=0.35), duration of HD <3 years versus ≥3 years were 1.04 (95%CI 0.99-1.09 p=1.00). The adverse event of this drug is minimal. Conclusions: Grazoprevir-elbasvir therapy in HD patient with chronic HCV is effective, and minimal adverse event. SVR12 is not influenced by either viral load, degree of fibrosis or duration of HD.

Abstrak :
Latar Belakang : Virus Hepatitis C (HCV) merupakan salah satu penyebab penyakit hati kronik yaitu hepatitis kronik, sirosis dan karsinoma hepatoseiuiar. Dari berbagai penelitian tentang HCV, didapatkan adanya hubungan antara penderita HCV dengan gangguan jiwa/psikiatrik, demikian pula berbagai penelitian tentang HCV dan terapi interferon (IFN) telah dilaporkan adanya efek samping berupa gejala neuropsikiatri seperti, malaise, futique, gangguan cemas, gangguan depresi, tentamen suicide dan psikotik. Prevalensi penelitian terakhir tentang gangguan jiwa pada penderita HCV dengan atau tanpa terapi IFN sekitar 32%. Tujuan : Untuk mendapatkan frekuensi dan jenis gangguan jiwa pada penderita hepatitis C di Poliklinik Hepatologi RSCM dan berbagai variabel yang mempengaruhinya. Metode : Penelitian ini menggunakan rancangan cross sectional, dilakukan pada 85 penderita HCV yang berobat di Poliklinik Hepatologi RSCM. Sampel diambil secara consecutive sampling. Instrumen yang digunakan adalah MINI (Mini International Neuropsychiatric Interview) ICD-10. Analisis statistik dilakukan dengan menggunakan SPSS for windows 10.0 dengan batas kemaknaan 0,05 serta regresi logistik. Hasil dan Simpulan : Frekuensi gangguan jiwa pada penderita HCV adalah 38 subyek (44,7%), dengan jenis gangguan jiwa antara lain ; Episode Depresi 12 subyek (14,0%), Gangguan yang berkaitan dengan Zat Psikoaktif (nikotin) 1 1 subyek (12,9%), Episode Depresi dan Gangguan Ansietas Menyeluruh 7 subyek (8,3%), Gangguan Ansietas Menyeluruh 5 subyek (5,9%) Episode Depresi dan Distimia 1 subyek (1,2%), Episode Depresi , Gangguan Ansietas Menyeluruh dan Gangguan berkaitan dengan Alkohol 1 subyek (1,2%), Gangguan yang berkaitan Zat Psikoaktif dan Gangguan berkaitan dengan Alkohol 1 subyek (1,2%). Pada 21 penderita HCV dengan terapi Interferon (IFN), terdapat 10 subyek mengalami gangguan jiwa. Tidak terdapat penilaian status mental (evaluasi psikiatrik) penderita HCV oleh tim terpaduu, saat sebelum, selama maupun sesudah dilakukan terapi IFN. Pada uji kemaknaan bivariat, terdapat hubungan bermakna antara status pemikahan (p0,001) dan risiko penularan HCV (p,0,000) dengan gangguan jiwa, sedangkan Pada uji kemaknaan multivariat, didapatkan hubungan bermakna antara risiko penularan HCV dengan gangguan jiwa (p0,001). ......Background : Hepatitis C Virus (HCV) is one of the causes of chronic liver disease, such as chronic hepatitis, cirrhosis, and hepatoceliular carcinoma. Several researches conducted on HCV, a correlation between patients with HCV and mental disorder is found, and also several researches on I-ICV and interferon therapy (IFN) have been reported on side effects neuropsychiatry symptoms such as malaise, Fatigue, anxiety disorder, suicidal attempt, and psychotic. The latest research prevalence on mental disorder in patients with HCV, with or without IFN reaches 32 %. Purpose : To attain the frequency and type of mental disorder in patients with HCV found in the hepatology outpatient clinic RSCM and the influencing variables. Method: This research is using cross-sectional design, conducted on 85 HCV patients seeking medical help in the hepatology outpatient clinic. The sample is obtained with consecutive sampling. The chosen instrument is MINI (Mini International Neuropsychiatry Interview) ICD-10. Statistic analysis is using SPSS for windows 10.0 with the level of significance 0.05 and the logistic regression. Result and Conclusion: The frequency of mental disorder in patients with HCV is 38 subjects (44.7%), with the following types of mental disorders; Depression Episode (14.0%), Mental Disorder related to Psychoactive Substance (nicotine) 11 subjects (12.9%), Depression Episode and Generalized Anxiety Disorder 7 subjects (8.3%), Generalized Anxiety Disorder 5 subjects (5.9%), Depression Episode and Mental Disorder related to Alcohol 1 subject (1.2%), Mental Disorder related to Psychoactive Substance and Mental Disorder related to Alcohol 1 subject (1.2%). In 21 HCV patients, with interferon therapy (IFN), 10 subjects suffer from mental disorder. There is no psychiatric evaluation in HCV patients, with a well-integrated team, as in before, during, and after the IFN therapy. In the bivariate test of significance, there is a significant relevance between the marital status (p 0.001) and the risk of transmission (p 0.000) with mental disorder, meanwhile in the multivariate test of significance, a significant correlation is found between the risk of HCV transmission and mental disorder (p 0.001).

Abstrak :
Background: Narcotics and psychoactive substances abuse, particularly by intravenous route, currently is a major health problem affecting young Indonesian people. Consequently, there is an increasing incidence of blood-borne viral diseases, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections. This study was aimed to investigate the prevalence of HCV and HIV co-infection among narcotics abusers in Pondok Indah Hospital, Jakarta. Method: This was a cross-sectional study in Pondok Indah Hospital, Jakarta using patients' medical records. Data from patients with the diagnosis of mental and behavioral disorders due to various psychoactive substances and HIV-related diseases were retrieved to obtain demographic characteristics, history of drug abuse and sewlogical testing. Patients were excluded if there were another organic mental disorders found or a history of blood transfusion prior to infection. Results: There were 157 cases of drug abuse collected between January 2000 and May 2005, 85.4% were men and their median age was 24 years old. The peak age group was 21-25 years old. Injection drug users (IDUs) were found in 72% of cases. Anti-HCV total antibody was found in 45.2% cases, including 2 non-IDUs, while anti-HIV antibody and combined anti-HCV/anti HIV antibodies were found in 13.4% and 7.6% cases, respectively. Anti-HCV positive patient are significantly younger than anti-HCV negative patients (27.9 ± 8.2 vs. 23.7 ± 4.4 years, p < 0.001), while the duration of use was not significantly correlated with HCV infection. Neither age nor duration of use was statistically significant with the presence of anti-HIV antibody. However, there is a significant correlation between the duration of drug abuse with HCV and HIV co-infection (6.0 ± 3.0 vs. 4.1 ± 2.8 years, p = 0.027). Conclusion: The prevalence of HCV and HIV co-infection among narcotics abusers in Pondok Indah Hospital was 7.6%. The emerging cases of hepatitis C and HIV infections during the last several years was significantly related to the increasing numbers of narcotics abusers.

Abstrak :
Aim: To investigate the expression CD4+ T cell and CD8+ T cell as well as TNF-a and INF-7 level on Citron ic hepatitis C. Methods: This is a cross-sectional study. Forty patients with chronic hepatitis C based on laboratory examination, who were collected from blood transition centers at Dn M. Djamil Hospital. The control group used forty healthy samples. Results: There were 40 chronic hepatitis C cases satisfying the inclusion criteria. We found that CD4+ T cells count 50.35 + 3.1 8%; CD8+ T cells count 59.37 + 3.52%; TNF-a level 22.03 :t 3.?2 pg/ml and INF-7 level 4.47 + 1.47 pg/ml. Conclusion: The chronic infection hepatitis C virus have given the effects on the immunocompetent cells which increased of CD4+, CD8+, TNF-a level and INF-y level.

Abstrak :
Latar belakang: Insidensi dan faktor risiko karsinoma hepatoseluler (KSH) pada pasien hepatitis C virus (HCV) yang sudah mencapai sustained virological response (SVR) pasca terapi direct acting antiviral (DAA) belum banyak diketahui. Mengingat terdapat perbedaan jenis DAA, genotype virus, dan profil pasien di Indonesia, dilakukan studi untuk menilai insidensi dan faktor-faktor yang memengaruhi KSH pada pasien HCV pasca SVR post terapi DAA. Tujuan: Mengetahui insidensi dan faktor-faktor yang memengaruhi kejadian KSH pada pasien HCV yang mencapai SVR pasca pengobatan DAA. Metode: Desain penelitian kohort retrospektif di RSUPN Cipto Mangunkusumo, sampel pasien HCV yang SVR pasca DAA tahun 2017 – 2019, diikuti hingga 2024. Pasien dilakukan skrining USG abdomen, alpha-fetoprotein (AFP) dan CT Scan abdomen 3 fase apabila terdapat indikasi. Dilakukan analisis deskriptif, bivariat dengan Fisher’s exact, dan multivariat dengan regresi logistik bila terdapat faktor risiko di analisis bivariat (p <0,25). Hasil: Dari 180 subjek penelitian, insidensi dan rasio insidensi KSH pada seluruh populasi mencapai 4,4% (rasio insidens 0,91/100PY). Terdapat hubungan signifikan dari analisis bivariat variabel sirosis hepatis (RR 10,5; IK 95% (1,32 – 83,5); p =0,0073) dan DM tipe 2 (RR 8,47; IK 95% (2,3 – 31,1) p = 0,0048). Terdapat hubungan signifikan dari analisis multivariat variabel DM tipe 2 (aRR 3,1; IK 95% (0,86 – 3,83); p=0,002). Kesimpulan: Insidensi KSH mencapai 4,4% dari total populasi. DM tipe 2 memiliki hubungan yang signifikan terhadap kejadian KSH pada pasien HCV yang mencapai SVR pasca pengobatan DAA. ......Background: The incidence and risk factors for hepatocellular carcinoma (HCC) in hepatitis C (HCV) patients who have achieved sustained virological response (SVR) after direct-acting antiviral (DAA) therapy are not well established. Considering there are differences in DAA types, virus genotypes, and patient profiles in Indonesia, this study was conducted to assess the incidence and factors influencing HCC in HCV patients after SVR post DAA therapy. Objective: To determine the incidence and factors influencing HCC in HCV patients achieving SVR after DAA treatment. Method: Retrospective cohort study conducted at Cipto Mangunkusumo National General Hospital, sample of HCV patients had SVR after DAA therapy in 2017 – 2019, followed until 2024. Patients were screened for abdominal ultrasound, alpha-fetoprotein (AFP) and 3-phase abdominal CT scan, if indicated. Descriptive, bivariate analysis with Fisher's exact, and multivariate analysis with logistic regression were conducted. Results: Among 180 subjects, the incidence and incidence ratio of HCC is 4.4% (0.91/100PY). Significant correlation in bivariate analysis from the variables liver cirrhosis (RR 10.5; CI 95% (1. 32 – 83.5); p = 0.0073) and type 2 DM (RR 8.47; CI 95% (2, 3 – 31.1) p = 0.0048). In multivariate analysis, there was significant correlation from type 2 DM variable (aRR 3.1; CI 95% (0.86 – 3.83); p=0.002). Conclusion: The incidence of HCC reaches 4.4% of the total population. Type 2 DM has significant correlation with the incidence of HCC in HCV patients who achieve SVR after DAA treatment.

Abstrak :
ABSTRAK
<

Karsinoma hepatoseluler (KHS) merupakan karsinoma primer tersering pada sel hati. Sebagian besar KHS disebabkan oleh virus hepatitis B (VHB) dan virus hepatitis C (VHC) yang memiliki patogenesis yang berbeda dalam menyebabkan KHS. Alfa-fetoprotein (AFP) sebagai penanda tumor pada KHS dan dipengaruhi oleh berbagai faktor, salah satunya status infeksi. Berbagai penelitian sudah dilakukan untuk mengetahui pengaruh pengaruh jenis virus penyebab KHS dengan kadar AFP namun hasilnya sangat beragam. Berdasarkan hal tersebut dan ditambah dengan belum adanya penelitian serupa yang menggunakan data pasien di Indonesia maka penelitian ini bertujuan untuk membandingkan kadar AFP pada pasien KHS terkait infeksi VHB terhadap VHC. Penelitian ini dilakukan dengan desain studi potong lintang menggunakan 199 data AFP pasien KHS yang terdiri dari 129 kasus KHS terkait VHB dan 70 kasus KHS terkait VHC. Dari penelitian ini didapatkan sebanyak 97% dan 87.3% pasien KHS terkait VHC dan VHB mengalami peningkatan kadar AFP secara berurutan. Nilai median kadar AFP pada pasien KHS terkait VHB adalah 419 IU/mL sedangkan pada pasien KHS terkait VHC sebesar 400 IU/mL. Perbedaan nilai tersebut memiliki nilai p = 0.97 dalam uji Mann-Whitney U sehingga disimpulan tidak ada perbedaan bermakna pada rerata kadar AFP antara pasien KHS terkait VHB dibanding dengan VHC.

---

ABSTRACT

Hepatocellular carcinoma (HCC) is the most primary common carcinoma in liver cells. Most HCC are caused by the hepatitis B virus and hepatitis C that have different pathogenesis in causing carcinoma. Alpha-fetoprotein as tumor marker in HCC is influenced by various factors, one of which is infection status. Various studies have been carried out to determine the influence of the types of viruses causing HCC with AFP levels but the results are very diverse. Based on this and coupled with the absence of similar studies using patient data in Indonesia, this study aims to compare AFP levels in HCC patients related to HBV and HCV. Using cross-sectional design, this study included 199 data of AFP in patient with HCC comprises of 129 cases of HCC related to HBV and 70 cases of HCC related to HCV. From this study, it was found that 97% and 87.3% of HCC patients related to HCV and HBV experienced an increase in AFP levels consecutively. The median value of AFP levels in HBV-related HCC patients was 419 IU / mL while in HCV-related HCC patients was 400 IU / mL. The difference in value has a p value = 0.97 in the Mann-Whitney U test thus it is concluded that there is no significant difference in AFP levels between HBV-related HCC patients compared with HCV-related HCC.